Clinical trial readout dates for Mineralys Therapeutics Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$2.2B
Cash & investments$625M~11 quarters at last loss rate
Recent 8-K filings2latest 2026-11-04
In progress, no date published
Phase 2Lorundrostat
Chronic Kidney Disease
date not published
Ongoing
Cash position
Mineralys Therapeutics Inc. reported $625M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $57M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates